Pancreatic cancer has no known cause, no early detection and no known cure. Over the past 40 years there has been no change to the survival rate of 7% past 5 years post diagnosis. Despite these facts, less than 2% of government cancer funding is dedicated to pancreatic cancer. This gap between lives lost and funding presents an enormous opportunity for donors to save and improve lives through research funding.
In 2016, PCCF created a multi-disciplinary partnership
between major cancer centres in Canada, called PancOne(™)
which aims to evaluate metastatic pancreatic cancer
molecular signature in a clinical trial setting.